Validation of SREBF2, LDLR, HMGCS1, and HMGCR antibodies. (A) Domain organization of human SREBF2 protein. Antibody epitope is within 455–469 aa. Cell lysates from (i) siRNA-control and siRNA-SREBF2, (ii) control plasmid and full-length cDNA expressing SREBF2. Black arrow: full-length SREBF2; blue arrow: N-terminal processed transcription domain. (B) Domain organization of human LDLR protein. Antibodies were produced using recombinant protein within 1–350 aa (for Proteintech, 10785–1-AP) or 500–550 aa (Novus, NBP1-06709-SS) for LDLR. Cell lysates from (i and iii) siRNA-control and siRNA-LDLR, and (ii and iv) control plasmid and full-length cDNA expressing GFP-LDLR. Black arrow: endogenous LDLR; green arrow: GFP-LDLR. (C) Domain organization of human HMGCS1 protein. Antibody was produced using recombinant protein within 171–520 aa. Cell lysates from (i) siRNA-control and siRNA-HMGCS1, and (ii) control plasmid and full-length cDNA expressing HMGCS1. Black arrow: endogenous HMGCS1. (D) Domain organization of human HMGCR protein. Cell lysates from (i) siRNA-control and siRNA-HMGCR, and (ii) control plasmid and full-length cDNA expressing HMGCR. Black arrow: endogenous HMGCR. ctrl, control.